• 1
    Neal B, MacMahon S, Chapman N, for the Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Lancet. 2000;356:19551964.
  • 2
    Ruggenenti P, Schieppati A, Remuzzi G. Progression, remission, regression of chronic renal diseases. Lancet. 2001; 357:16011608.
  • 3
    Hebert LA, Kusek JW, Greene T, et al., for the Modification of Diet in Renal Disease Study Group. Effects of blood pressure control on progressive renal disease in blacks and whites. Hypertension. 1997;30:428435.
  • 4
    Cushman WC. The burden of uncontrolled hypertension: morbidity and mortality associated with disease progression. J Clin Hypertens (Greenwich). 2003;5(3 suppl 2): 1422.
  • 5
    Elliott WJ. The economic impact of hypertension. J Clin Hypertens (Greenwich). 2003;5(3 suppl 2):313.
  • 6
    Chobanian AV, Bakris GL, Black HR, et al., and the National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:25602572.
  • 7
    Lewington S, Clarke R, Qizilbash N, et al., for the Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality. Lancet. 2002;360:19031913.
  • 8
    Bakris GL, Williams M, Dworkin M, et al., for the National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Preserving renal function in adults with hypertension and diabetes: a consensus approach. Am J Kidney Dis. 2000;36:646661.
  • 9
    Arauz-Pacheco C, Parrott MA, Raskin P. Treatment of hypertension in adults with diabetes. Diabetes Care. 2003;26(suppl 1):S80S82.
  • 10
    Douglas JG, Bakris GL, Epstein M, et al., for the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Management of high blood pressure in African Americans. Arch Intern Med. 2003; 163:525541.
  • 11
    Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med. 1998;339:19571963.
  • 12
    Cheng JW, Kalis MM, Feifer S. Patient-reported adherence to guidelines of the Sixth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Pharmacotherapy. 2001;21:828841.
  • 13
    Zyczynski TM, Coyne KS. Hypertension and current issues in compliance and patient outcomes. Curr Hypertens Rep. 2000;2:510514.
  • 14
    Hansson L, Zanchetti A, Carruthers SG, et al., for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:17551762.
  • 15
    UK Prospective Diabetes Study Group. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. BMJ. 1998;317:720726.
  • 16
    Wright JT Jr, Agodoa L, Contreras G, et al., for the African American Study of Kidney Disease and Hypertension Study Group. Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med. 2002;162:16361643.
  • 17
    Sica DA. Are current strategies for treating hypertension effective? J Clin Hypertens (Greenwich). 2003;5(3 suppl 2):2332.
  • 18
    Neutel JM. Low-dose antihypertensive combination therapy: its rationale and role in cardiovascular risk management. Am J Hypertens. 1999;12:73S79S.
  • 19
    Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987:40:373383.
  • 20
    Quan H, Parsons GA, Ghali WA. Validity of information on comorbidity derived from ICD-9-CCM administrative data. Med Care. 2002:40;675685.
  • 21
    Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988–2000. JAMA. 2003;290:199206.
  • 22
    Caro JJ, Speckman JL, Salas M, et al. Effect of initial drug choice on persistence with antihypertensive therapy: the importance of actual practice data. CMAJ. 1999;160:4146.
  • 23
    Mancia G, Frattola A, Parati G, et al. Blood pressure variability and organ damage. J Cardiovasc Pharmacol. 1994;24(suppl A):S6S11.
  • 24
    Mancia G, Grassi G. Mechanisms and clinical implications of blood pressure variability. J Cardiovasc Pharmacol. 2000; 35(suppl):S15S19.
  • 25
    Chasen C, Muller JE. Cardiovascular triggers and morning events. Blood Press Monit. 1998;3:3542.
  • 26
    Mulé G, Nardi E, Andronico G, et al. Relationships between 24 h blood pressure load and target organ damage in patients with mild-to-moderate essential hypertension. Blood Press Monit. 2001;6:115123.
  • 27
    Monane M, Bohn RL, Gurwitz JH, et al. The effects of initial drug choice and comorbidity on antihypertensive therapy adherence: results from a population-based study in the elderly. Am J Hypertens. 1997; 10:697704.
  • 28
    Feldman R, Bacher M, Campbell N, et al. Adherence to pharmacologic management of hypertension. Can J Public Health. 1998;89:I16I18.
  • 29
    Weir MR, Maibach EW, Bakris GL, et al. Implications of a health lifestyle and medication analysis for improving hypertension control. Arch Intern Med. 2000; 160:481490.
  • 30
    Peterson AM, Takiya L, Finley R. Meta-analysis of trials of interventions to improve medication adherence. Am J Health Syst Pharm. 2003;60:657665.
  • 31
    Steiner JF, Prochazka AV. The assessment of refill compliance using pharmacy records: methods, validity, and applications. J Clin Epidemiol. 1997;50:105116.
  • 32
    Maronde RF, Chan LS, Larsen FJ, et al. Underutilization of antihypertensive drugs and associated hospitalization. Med Care. 1989;27:11591166.
  • 33
    Psaty BM, Koepsell TD, Wagner EH, et al. The relative risk of incident coronary heart disease associated with recently stopping the use of beta blockers. JAMA. 1990;263:16531657.
  • 34
    Stergachis A, Sheingold S, Luce BR, et al. Medical care and cost outcomes after pentoxifylline treatment for peripheral arterial disease. Arch Intern Med. 1992;152:12201224.
  • 35
    McCombs JS, Nichol MB, Newman CM, et al. The costs of interrupting antihypertensive drug therapy in a medical population. Med Care. 1994;32:214226.
  • 36
    Johnson ES, Mozaffari E. Measuring patient persistency with drug therapy using methods for the design and analysis of natural history studies. Am J Manag Care. 2002;8:S249S254.
  • 37
    Messerli FH, Weir MR, Neutel JM. Combination therapy of amlodipine/benazepril versus monotherapy of amlodipine in a practice-based setting. Am J Hypertens. 2002;15:550556.
  • 38
    Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253259.
  • 39
    Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension. The cycle repeats. Drugs. 2002;62:443462.
  • 40
    Fogari R, Corea L, Cardoni O, et al. Combined therapy with benazepril and amlodipine in the treatment of hypertension inadequately controlled by an ACE inhibitor alone. J Cardiovasc Pharmacol. 1997;30:497503.
  • 41
    Frishman WH, Ram CV, McMahon FG, et al. for the Benazepril/Amlodipine Study Group. Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebo-controlled, parallel-group study. J Clin Pharmacol. 1995; 35:10601066.
  • 42
    Kuschnir E, Acuna E, Sevilla D, et al. Treatment of patients with essential hypertension: amlodipine 5 mg/benazepril 20 mg compared with amlodipine 5 mg, benazepril 20 mg, and placebo. Clin Ther. 1996;18:12131224.
  • 43
    Pool J, Kaihlanen P, Lewis G, et al. Once-daily treatment of patients with hypertension: a placebo-controlled study of amlodipine and benazepril vs. amlodipine or benazepril alone. J Hum Hypertens. 2001:15;495498.